Martin "Pharma Bro" Shkreli was hit with a lawsuit from a digital art collective on Monday, which alleges that he made copies of the rare 'Once Upon a Time In Shaolin' album by the Wu-Tang Clan and shared it, violating their deal.
Cryptocurrency collective PleasrDAO, which bought the one-of-a-kind album in 2021, filed the complaint. Martin Shkreli Accused of Copying Wu-Tang Clan’s Once Upon a Time in Shaolin in Lawsuit Eddie Fu
Martin Shkreli, the infamous “pharma bro” who raised the price of a life-saving drug by 5,000%, went toe-to-toe with the Wu-Tang Clan, and found himself sentenced to seven years in prison for defrauding investors, has received an early release after less than five years served, according to his attorney. “I am pleased to report that Martin Shkreli has been released from Allenwood prison and transferred to a BOP halfway house after completing all programs that allowed for his prison sentence to be shortened,” Ben Brafman, his lawyer, said in a statement to The Washington Post. According to a spokesperson for the Federal Bureau of Prisons, he’ll remain in the halfway house until mid-September. Shkreli had been accused of taking stock from his biotechnology firm Retrophin and u...
Disgraced pharmaceutical CEO Martin Shkreli has been banned from the industry forever, and has also been ordered to return the $64.6 million in profits he made by price-gouging the drug Daraprim. The ruling in U.S. District Court in Manhattan on Friday came in response to a multi-state lawsuit accusing Shkreli of illegal and monopolistic behavior. According to the Associated Press, over the course of a seven-day trial last month, prosecutors presented recordings of conversations that appeared to show Shkreli continuing to exert control over his company, Vyera Pharmaceuticals LLC, while he was behind bars. Those recordings also indicated that Shkreli had plans to prevent generic versions of Daraprim, a life-saving drug used to combat a rare parasitic disease, from being sold. Back in ...
Source: Drew Angerer / Getty One of the most unique album releases of all time eventually ended up being a reminder that money does not buy you class. The story behind the purchase of Wu-Tang Clan’s one of one project is coming to your favorite streaming platform. As spotted on Hype Beast the album the Hip-Hop world wanted to hear but may never be able to is now the subject of an upcoming movie. The story of how the iconic group’s seventh project was sold at auction and ended up in the hands of pharamadouche poster boy Martin Shkreli will soon be coming to Netflix. According to the report Paul Downs Colaizzo of Brittany Runs A Marathon has been slotted as director. The untitled project will be written by Ian Edelman (American Sole) and produced by Brad Pitt’s Plan B Entertainment...
The relatively short history of Wu-Tang Clan’s seventh studio album, 2015’s one-of-a-kind Once Upon a Time in Shaolin, is already something of a legend. It’s a weird, wild tale involving pharmadouche Martin Shkreli, $2 million auctions, diss tracks, and federal forfeitures. Now, the whole sordid story will be told in a new Netflix film. The announcement of the project was tucked into a press release about screenwriter Ian Edelman’s new movie, American Sole (starring Pete Davidson and O’Shea Jackson Jr.). As Collider reports, Brittany Runs a Marathon director Paul Downs Colaizzo will helm the project, with Wu-Tang’s own RZA producing alongside Brad Pitt’s Plan B. Edelman will be working off Colaizzo’s original draft of the script. For those who don’t know, the Wu-Tang Clan only produced one...
Looks like America will need to come up with another way of finding a COVID-19 vaccine: a federal judge has denied Martin Shkreli’s request for an early release from prison. Last month, Shkreli petitioned the court for an early release, saying that he had “been conducting significant research into developing molecules to inhibit the coronavirus.” “Mr. Shkreli has spent countless hours while incarcerated researching disease treatments and possible cures for COVID-19,” his lawyers wrote in a formal request. “His current project has been well received. One company is prepared to begin working on clinical trials of Mr. Shkreli’s work within weeks.” The judge wasn’t buying it, however. TMZ reports that the judge dismissed the pharmadouche’s claims as yet another example of the “delusional self-...